APLM
Price
$22.28
Change
+$1.01 (+4.75%)
Updated
Oct 22 closing price
Capitalization
64.95M
Intraday BUY SELL Signals
PRAX
Price
$258.92
Change
+$2.45 (+0.96%)
Updated
Oct 22 closing price
Capitalization
7.23B
13 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

APLM vs PRAX

APLM vs PRAX Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
APLM vs. PRAX commentary
Oct 23, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is APLM is a Hold and PRAX is a StrongBuy.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for APLM with price predictions
Oct 22, 2026

APLM's Indicator enters downward trend

The Aroon Indicator for APLM entered a downward trend on October 22, 2026. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 196 similar instances where the Aroon Indicator formed such a pattern. In 177 of the 196 cases the stock moved lower. This puts the odds of a downward move at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

APLM moved below its 50-day moving average on October 06, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for APLM crossed bearishly below the 50-day moving average on October 12, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 11 of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 85%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where APLM declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 39 of 63 cases where APLM's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 62%.

The Momentum Indicator moved above the 0 level on October 22, 2026. You may want to consider a long position or call options on APLM as a result. In 67 of 104 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 64%.

The Moving Average Convergence Divergence (MACD) for APLM just turned positive on October 22, 2026. Looking at past instances where APLM's MACD turned positive, the stock continued to rise in 27 of 47 cases over the following month. The odds of a continued upward trend are 57%.

Following a +8.82% 3-day Advance, the price is estimated to grow further. Considering data from situations where APLM advanced for three days, in 137 of 173 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.

APLM may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is 45 (best 1 - 100 worst), indicating steady price growth. APLM’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is 63 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 67 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.121) is normal, around the industry mean (2.973). P/E Ratio (-1.485) is within average values for comparable stocks, (-1.705). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.121) among similar stocks. P/S Ratio (3.761) is also within normal values, averaging (438.009).

The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. APLM’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

A.I.Advisor
a Summary for PRAX with price predictions
Oct 22, 2026

PRAX sees its Stochastic Oscillator ascending out of oversold territory

On October 20, 2026, the Stochastic Oscillator for PRAX moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 55 instances where the indicator left the oversold zone. In 49 of the 55 cases the stock moved higher in the following days. This puts the odds of a move higher at over 89%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where PRAX's RSI Indicator exited the oversold zone, 29 of 33 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 88%.

The Moving Average Convergence Divergence (MACD) for PRAX just turned positive on October 20, 2026. Looking at past instances where PRAX's MACD turned positive, the stock continued to rise in 38 of 43 cases over the following month. The odds of a continued upward trend are 88%.

Following a +9.40% 3-day Advance, the price is estimated to grow further. Considering data from situations where PRAX advanced for three days, in 258 of 304 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.

PRAX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The 50-day moving average for PRAX moved below the 200-day moving average on October 22, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where PRAX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 83%.

The Aroon Indicator for PRAX entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 17 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.391) is normal, around the industry mean (2.973). P/E Ratio (-19.978) is within average values for comparable stocks, (-1.705). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.121) among similar stocks. P/S Ratio (1000.000) is also within normal values, averaging (438.009).

The Tickeron PE Growth Rating for this company is 25 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is 63 (best 1 - 100 worst), indicating steady price growth. PRAX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PRAX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

FUNDAMENTALS RATINGS
PRAX: Fundamental Ratings
PRAX
OUTLOOK RATING
1..100
61
VALUATION
overvalued / fair valued / undervalued
1..100
17
Undervalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
97
PRICE GROWTH RATING
1..100
63
P/E GROWTH RATING
1..100
25
SEASONALITY SCORE
1..100
50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
APLMPRAX
RSI
ODDS (%)
N/A
Bullish Trend 1 day ago
88%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
62%
Bullish Trend 1 day ago
89%
Momentum
ODDS (%)
Bullish Trend 1 day ago
64%
N/A
MACD
ODDS (%)
Bullish Trend 1 day ago
57%
Bullish Trend 1 day ago
88%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
55%
Bullish Trend 1 day ago
87%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
88%
Bearish Trend 1 day ago
83%
Advances
ODDS (%)
Bullish Trend 4 days ago
79%
Bullish Trend 3 days ago
85%
Declines
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 9 days ago
83%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
81%
Bullish Trend 1 day ago
85%
Aroon
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
83%
COMPARISON
Comparison
Oct 23, 2026
Stock price -- (APLM: $22.28 vs. PRAX: $258.92)
Brand notoriety: APLM and PRAX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: APLM: 45% vs. PRAX: 69%
Market capitalization -- APLM: $64.95M vs. PRAX: $7.23B
APLM [@Biotechnology] is valued at $64.95M. PRAX’s [@Biotechnology] market capitalization is $7.23B. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $135.64B. The average market capitalization across the [@Biotechnology] industry is $2.14B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

APLM’s FA Score shows that 0 FA rating(s) are green while PRAX’s FA Score has 2 green FA rating(s).

  • APLM’s FA Score: 0 green, 5 red.
  • PRAX’s FA Score: 2 green, 3 red.
According to our system of comparison, PRAX is a better buy in the long-term than APLM.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

APLM’s TA Score shows that 5 TA indicator(s) are bullish while PRAX’s TA Score has 5 bullish TA indicator(s).

  • APLM’s TA Score: 5 bullish, 4 bearish.
  • PRAX’s TA Score: 5 bullish, 3 bearish.
According to our system of comparison, PRAX is a better buy in the short-term than APLM.

Price Growth

APLM (@Biotechnology) experienced а +10.41% price change this week, while PRAX (@Biotechnology) price change was +4.30% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.17%. For the same industry, the average monthly price growth was -18.21%, and the average quarterly price growth was -15.24%.

Reported Earning Dates

PRAX is expected to report earnings on Nov 04, 2026.

Industries' Descriptions

@Biotechnology (-1.17% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
APLM
Daily Signal:
Gain/Loss:
PRAX
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
DIVZ38.010.43
+1.14%
Polen Dividend Income ETF (DIVZ)
FNX139.610.76
+0.54%
First Trust Mid Cap Core AlphaDEX Fund (FNX)
SHUS50.89N/A
N/A
Stratified LargeCap Hedged ETF (SHUS)
TKNQ23.83-0.74
-3.03%
Amplify Tokenization Technology Leaders ETF (TKNQ)
SSK13.99-0.65
-4.44%
REX-Osprey SOL + Staking ETF (SSK)